The reaction of the imidazolyl-4(5)-phosphane ligands 2-isopropylimidazol-4(5)yl-diphenylphosphane (4-MIPiPr) and tris(2-isopropylimidazol-4(5)yl)phosphane (4-TIPiPr) towards gold(I) has been explored and compared to those of analogous 1-methylimidazol-2-ylphosphane ligands. The structure of [(4-MIPiPr)AuCl] (4) shows a linear P–Au–Cl coordination, whereas the 4-TIPiPr ligand forms a dinuclear complex [(4-TIPiPr)Au}2]Cl2 (5). Here, 4-TIPiPr bridges two gold(I) atoms in a head-to-tail P,N fashion. Complex 5 forms in the presence of the hard Lewis acid ZnCl2 the bimetallic complex [AuCl(4-TIPiPr)ZnCl]Cl (6), in which 4-TIPiPr bridges the two metal centers. In accordance with the HSAB concept the Au(I) atom is coordinated by the P atom and the zinc(II) by three N atoms in a N,N,N fashion. The solid-state structures of the complexes 4–6 have been elucidated by single-crystal X-ray analysis. The Au(I)–Au(I) contact in 5 is 2.8821(15) Å. The biological activities of all imidazol-2-yl- and imidazol-4(5)-ylphosphane gold(I) complexes towards nine human cancer cell lines including seven ovarian cancer cell lines of different sensitivity towards cisplatin and two leukemia cell lines have been explored.
咪唑基-4(5)-
膦配体2-异丙基咪唑-4(5)基-
二苯基膦(4-MIPiPr)和三(
2-异丙基咪唑-4(5)基)膦(4-TIPiPr)对
金的反应(I) 已被探索并与类似的 1-甲基
咪唑-2-基
膦配体进行比较。 [(4-MIPiPr)AuCl] (4) 的结构显示出线性 P-Au-Cl 配位,而 4-TIPiPr
配体形成双核配合物 [(4-TIPiPr)Au}2]Cl2 (5)。此处,4-TIPiPr 以头尾相连的 P,N 方式桥接两个
金 (I) 原子。配合物 5 在硬
路易斯酸 ZnCl2 存在下形成双
金属配合物 [AuCl(4-TIPiPr)ZnCl]Cl (6),其中 4-TIPiPr 桥接两个
金属中心。根据 H
SAB 概念,Au(I) 原子由 P 原子配位,
锌(II) 原子由三个 N 原子以 N、N、N 方式配位。配合物 4-6 的固态结构已通过单晶 X 射线分析阐明。 5 中的 Au(I)-Au(I) 接触面积为 2.8821(15) Å。已探索所有
咪唑-2-基-和
咪唑-4(5)-基膦
金(I)复合物对九种人类癌
细胞系(包括七种对
顺铂具有不同敏感性的卵巢癌
细胞系和两种白血病
细胞系)的
生物活性。